Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors.
The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents.
The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples.
Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer.
The focus for Cure51 is initially to start with 3 types of particularly agressive cancers and will naturally expand to other indications and therapeutic areas to capitalize on its exclusive and unprecedented set of data and discovery pipelines.
Company Details
- Employees
- 50
- Founded
- -
- Address
- Paris, 75009, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.cure51.com
- Keywords
- (AWS).
- HQ
- Paris
Cure51 Questions
Cure51's website is https://www.cure51.com
Cure51's LinkedIn profile is https://fr.linkedin.com/company/cure51
Cure51 has
50 employees.
View email and phone details for 50
employees at Cure51.
Cure51's industry is
Biotechnology Research
Cure51's top competitors are
Latent Labs,
Diabeloop,
Bioptimus,
Aqemia,
Rebrain,
Sofinnova Partners,
Raidium,
Biocortex,
Owkin,
Orakl Oncology.
Cure51's categories are Biotechnology Research
Cure51's founding year is 2021
